

**UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY**

In re: Valsartan, Losartan and
Irbesartan Products Liability Litigation

***THIS DOCUMENT RELATES TO
ALL CASES***


} MDL No. 2875
}
} Civil No. 1:19-md-2875 (RBK/KW)
}
} Honorable Robert B. Kugler
}

**NOTICE OF VOLUNTARY DISMISSAL
WITHOUT PREJUDICE AS TO PERIPHERAL
DEFENDANT LEGACY PHARMACEUTICAL PACKAGING, LLC**

WHEREAS the Court entered Case Management Order No. 15-A, which provides a mechanism for certain defendants to obtain a without prejudice dismissal from all cases pending in this MDL alleging claims in connection with allegedly contaminated losartan- and/or irbesartan-containing drugs (“LCDs” or “VCDs”);


WHEREAS, Legacy Pharmaceutical Packaging, LLC, having provided the information and documents required by Case Management Order No. 15-A, and having agreed to the tolling provisions therein;

IT IS HEREBY STIPULATED AND AGREED between Plaintiffs Executive Committee and Defendant Legacy Pharmaceutical Packaging, LLC, that all current cases pending and all future cases to be filed in this MDL alleging claims against Defendant Legacy Pharmaceutical Packaging, LLC in connection with allegedly contaminated LCDs or ICDs be and hereby are dismissed without prejudice.


On behalf of Plaintiffs Executive Committee

By: George T. Williamson

Dated: 8/31/2021


On behalf of Peripheral Defendant
Legacy Pharmaceutical Packing,
LLC

By: Britton L. St. Onge, Esq.

Dated: 6/4/2021